Alliancebernstein L.P. Acquires 175,859 Shares of UroGen Pharma Ltd. (NASDAQ:URGN)

Alliancebernstein L.P. boosted its holdings in UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) by 751.5% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 199,259 shares of the company's stock after purchasing an additional 175,859 shares during the quarter. Alliancebernstein L.P. owned 0.85% of UroGen Pharma worth $2,122,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the business. KLP Kapitalforvaltning AS acquired a new stake in shares of UroGen Pharma in the fourth quarter valued at approximately $59,000. BNP Paribas Financial Markets increased its stake in UroGen Pharma by 221.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 8,546 shares of the company's stock worth $109,000 after acquiring an additional 5,890 shares during the period. Oppenheimer & Co. Inc. acquired a new position in UroGen Pharma in the 4th quarter valued at $126,000. SG Americas Securities LLC raised its holdings in UroGen Pharma by 44.1% in the 4th quarter. SG Americas Securities LLC now owns 20,269 shares of the company's stock valued at $216,000 after acquiring an additional 6,207 shares in the last quarter. Finally, FMR LLC lifted its position in shares of UroGen Pharma by 575.1% during the 3rd quarter. FMR LLC now owns 23,090 shares of the company's stock valued at $293,000 after acquiring an additional 19,670 shares during the period. Institutional investors own 91.29% of the company's stock.

UroGen Pharma Trading Up 4.0 %

URGN stock traded up $0.39 during trading on Tuesday, hitting $10.05. The company had a trading volume of 378,527 shares, compared to its average volume of 511,867. UroGen Pharma Ltd. has a one year low of $8.94 and a one year high of $20.70. The company has a current ratio of 9.00, a quick ratio of 8.77 and a debt-to-equity ratio of 4.77. The business has a 50-day moving average of $10.47 and a 200-day moving average of $11.14. The stock has a market cap of $463.24 million, a PE ratio of -3.19 and a beta of 0.80.

UroGen Pharma (NASDAQ:URGN - Get Free Report) last released its earnings results on Monday, March 10th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.69) by ($0.11). The company had revenue of $24.57 million during the quarter, compared to analyst estimates of $25.25 million. Research analysts predict that UroGen Pharma Ltd. will post -3.12 earnings per share for the current fiscal year.

Insider Buying and Selling at UroGen Pharma

In other news, General Counsel Jason Drew Smith sold 7,379 shares of the business's stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $11.14, for a total transaction of $82,202.06. Following the completion of the sale, the general counsel now owns 26,468 shares in the company, valued at $294,853.52. The trade was a 21.80 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Mark Schoenberg sold 4,551 shares of the company's stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $11.14, for a total value of $50,698.14. Following the transaction, the insider now directly owns 145,666 shares in the company, valued at $1,622,719.24. The trade was a 3.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 5.10% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. HC Wainwright dropped their price target on UroGen Pharma from $64.00 to $55.00 and set a "buy" rating for the company in a research note on Tuesday, March 11th. LADENBURG THALM/SH SH initiated coverage on shares of UroGen Pharma in a research report on Wednesday, February 19th. They issued a "buy" rating and a $31.00 target price on the stock. Scotiabank began coverage on UroGen Pharma in a report on Wednesday, April 16th. They set a "sector outperform" rating and a $23.00 price target on the stock. D. Boral Capital reiterated a "buy" rating and issued a $25.00 price objective on shares of UroGen Pharma in a report on Monday, March 10th. Finally, The Goldman Sachs Group cut their target price on shares of UroGen Pharma from $22.00 to $16.00 and set a "neutral" rating on the stock in a research report on Thursday, April 17th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $32.86.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.